Outcomes of Chemoradiotherapy With 5-Fluorouracil and Mitomycin C for Anal Cancer in Immunocompetent Versus Immunodeficient Patients

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 143-149

  Seo, Yuji ^a   Kinsella, Michael T ^a   Reynolds, Harry L ^a   Chipman, Gregory ^a   Remick, Scot C ^a   Kinsella, Timothy J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anal squamous cell carcinoma; Combined modality treatment; HIV; Immunosuppression

Indexed keywords

5-FLUOROURACIL; ACUTE TOXICITY; ANAL CANCER; ANAL SQUAMOUS CELL CARCINOMA; CHEMORADIOTHERAPY; CLINICAL STUDY; COLOSTOMY-FREE SURVIVAL; COMBINED MODALITY THERAPY; COMBINED MODALITY TREATMENT; CONCURRENT CHEMORADIOTHERAPY; DISEASE-SPECIFIC SURVIVALS; HAZARD RATIO; HIV; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSION; MITOMYCIN; MITOMYCIN C; ORGAN TRANSPLANTS; OVERALL SURVIVAL; PRE-TREATMENT; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY; TREATMENT OUTCOMES; TUMOR SIZE;

CELL MEMBRANES; CHEMOTHERAPY; RADIOTHERAPY; THREE DIMENSIONAL; TOXICITY;

BIOINFORMATICS;

FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ANUS CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COLOSTOMY; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RADIATION DOSE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME; UROGENITAL TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CD4 LYMPHOCYTE COUNT; COLOSTOMY; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MITOMYCIN; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 67749100641     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.046     Document Type: Article

References (23)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Frisch M., Fenger C., van den Brule A.J., et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 59 (1999) 753-537
3. Frisch M., Biggar R.J., and Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92 (2000) 1500-1510
4. Clifford G.M., Polesel J., Rickenbach M., et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97 (2005) 425-432
5. Chiao E.Y., Krown S.E., Stier E.A., and Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 40 (2005) 451-455
6. Ryan D.P., Compton C.C., and Mayer R.J. Carcinoma of the anal canal. N Engl J Med 342 (2000) 792-800
7. Epidermoid anal cancer. Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348 (1996) 1049-1054
8. Bartelink H., Roelofsen F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15 (1997) 2040-2049
9. Ajani J.A., Winter K.A., Gunderson L.L., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 299 (2008) 1914-1921
10. Eng C. Anal cancer: Current and future methodology. Cancer Invest 24 (2006) 535-544
11. Oehler-Janne C., Huguet F., Provencher S., et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: A multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 26 (2008) 2550-2557
12. Blazy A., Hennequin C., Gornet J.M., et al. Anal carcinomas in HIV-positive patients: High-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 48 (2005) 1176-1181
13. Stadler R.F., Gregorcyk S.G., Euhus D.M., et al. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum 47 (2004) 1305-1309
14. Hoffman R., Welton M.L., Klencke B., Weinberg V., and Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 44 (1999) 127-131
15. Wexler A., Berson A.M., Goldstone S.E., et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: Outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 51 (2008) 73-81
16. Chiao E.Y., Giordano T.P., Richardson P., and El-Serag H.B. Human immunodeficiency virus-associated squamous cell cancer of the anus: Epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 26 (2008) 474-479
17. Kim J.H., Sarani B., Orkin B.A., et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum 44 (2001) 1496-1502
18. th Edition (2002), Springer, New York
19. Flam M., John M., Pajak T.F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14 (1996) 2527-2539
20. Mell L.K., Schomas D.A., Salama J.K., et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 1431-1437
21. Mell L.K., Kochanski J.D., Roeske J.C., et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 1356-1365
22. Pajonk F., Himmelsbach J., Riess K., Sommer A., and McBride W.H. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62 (2002) 5230-5235
23. Persad G.C., Little R.F., and Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol 26 (2008) 1027-1032